Showing results (491-500 of 554) with videos related to
Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.Annals of Surgical Oncology|July 11, 2013
Age as a prognostic factor in patients with localized melanoma and regional metastasesCharles M Balch, Seng-jaw Soong, Jeffrey E Gershenwald, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2020
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell CarcinomaMiriam Ficial, Opeyemi A Jegede, Miriam Sant'Angelo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma PatientsThomas Denize, Opeyemi A Jegede, Sayed Matar, et al.Journal for Immunotherapy of Cancer|September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.Cancer Immunology Research|May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanomaF Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.Cancer Medicine|November 2, 2025
Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor OutcomesHeather Derry-Vick, Neil J Shah, Jaeil Ahn, et al.NPJ Precision Oncology|November 14, 2023
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastasesGino K In, Jennifer R Ribeiro, Jun Yin, et al.Pageof 56